drugset / Trial / NCT00455858

Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

NCT00455858

Phase 4 Completed 87 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type 2 diabetes mellitus in Korea.

Timeline

Start
2007-11
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin detemir Protein / enzyme biologic Subcutaneous